Abstract

The European Medicines Agency on Nov. 18 recommended a marketing authorization for vandetanib, a drug to treat thyroid cancer, and extended indications on two more oncology drugs, cetuximab and trastuzumab. Vandetanib (AstraZeneca), will be authorized throughout the European Union to treat aggressive and symptomatic medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease. It was approved by the U.S. Food and Drug Administration in April for the...